Healthcare Industry News: HSMN NewsFeed
News Release - August 8, 2017
First Patient Treated with Varian HyperArc High Definition RadiotherapyPatient treated at cancer care center in Italy
PALO ALTO, Calif., Aug. 8, 2017 -- (Healthcare Sales & Marketing Network) -- Varian Medical Systems (NYSE: VAR) today announced the first cancer patient was treated using the company's HyperArc™ High Definition Radiotherapy (HDRT), a new type of radiosurgery treatment, at Sacro Cuore Don Calabria Cancer Care Center in Negrar-Verona, Italy. With HyperArc, clinicians can deliver more compact radiation doses that closely conform to the size, shape, and location of tumors while sparing more surrounding healthy tissue.
"HyperArc HDRT allows us to deliver state-of-the-art radiosurgery to highly complex cases efficiently and with a very high degree of dose compactness and conformity," said Prof. Filippo Alongi, director of Radiation Oncology at Sacro Cuore Don Calabria Cancer Care Center and associate professor of Radiation Oncology at Brescia University. "The first patient we treated with HyperArc was a complex case of multiple intracranial metastases and we were impressed with the quality and efficiency of the treatment. We now look forward to following the patient and further using HyperArc to manage the disease."
"We are very excited about this first treatment using HyperArc as we usher in a new era of precision in radiotherapy and radiosurgery for cancer patients," said Kolleen Kennedy, president of Varian Oncology Systems business.
HyperArc is designed to capitalize on the unique capabilities of Varian's TrueBeam™ and EDGE™ treatment platforms. HyperArc treatments exploit specific capabilities of the platforms to deliver more compact radiation doses that can fully saturate a targeted tumor and "fall off" sharply outside the target zone, minimizing and, where necessary, even eliminating dose to specific organs requiring more protection.
The treatment planning for HyperArc is supported by Varian's Eclipse™ treatment planning software and is 510(k) pending. HyperArc treatment delivery has received CE mark and FDA 510(k) clearance and is not for sale in all markets.
About Varian Medical Systems
Varian Medical Systems focuses energy on saving lives and is the world's leading manufacturer of medical devices and software for treating and managing cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,600 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
About Sacro Cuore Don Calabria Cancer Care Center
Sacro Cuore Don Calabria Cancer Care Center is the biggest private Cancer Care Center in North-Est of Italy. The center is focused on radiosurgery and treats more than 1200 cases per year, 400 of which are SRS, SBRT and extremely hypofractionated treatments, all by means of TrueBeam® with FFF mode and RapidArc® technology. In the last two years, the faculty of Sacro Cuore has published more than 50 articles on Radiation Oncology with an impact factor more than 200 points. For more information, visit www.sacrocuoredoncalabria.it/Servizi-di-diagnosi-e-cura/Radioterapia-Oncologica/Presentazione/
Source: Varian Medical Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsVarian Halcyon Treatment System Receives ANVISA Registration in Brazil
Treatments Commence at Two Algerian Hospitals Equipped with Modern Varian Radiotherapy Systems
Varian Selected in Multi-Year Project to Replace Radiotherapy Treatment Equipment at Copenhagen's Rigshospitalet and Herlev Hospital